Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HTI), sold 25,000 shares at $8.00 ($201K) on 2007-04-02, disclosed to the SEC on 2007-04-04.
Scheduled sale ($201k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.00 | 1,075 | $9K | 4.3% |
| 2 | $8.01 | 3,500 | $28K | 13.9% |
| 3 | $8.02 | 525 | $4K | 2.1% |
| 4 | $8.03 | 700 | $6K | 2.8% |
| 5 | $8.04 | 2,900 | $23K | 11.6% |
| 6 | $8.05 | 6,690 |
| $54K |
| 26.8% |
| 7 | $8.06 | 497 | $4K | 2.0% |
| 8 | $8.07 | 5,400 | $44K | 21.7% |
| 9 | $8.08 | 1,824 | $15K | 7.3% |
| 10 | $8.09 | 789 | $6K | 3.2% |
| 11 | $8.10 | 900 | $7K | 3.6% |
| 12 | $8.12 | 200 | $2K | 0.8% |
| Total | $8.05 avg | 25,000 | $201K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |